Screener
Regeneron Pharmaceuticals REGN Other products — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| U.S. | 342.6 | 247.8 | 628.7 | 440.3 |
| Rest of world | 146.8 | 128.7 | 298.9 | 221.3 |
| Global | 489.4 | 376.5 | 927.6 | 661.6 |
| U.S. | 74.7 | 65.8 | 141.3 | 122.6 |
| U.S. | 53.3 | 41.2 | 99.0 | 72.1 |
| Global | 16.5 | — | 27.7 | — |
| Global | — | — | 31.3 | — |
| $1,642.4 | $1,631.0 | $3,176.9 | $3,046.6 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's other products — revenue?
- Regeneron Pharmaceuticals (REGN) reported other products — revenue of $0 in Q2 2026.
- What does other products — revenue mean?
- This metric represents the aggregate revenue generated from the company's secondary or smaller-scale pharmaceutical products that are not classified under the primary blockbuster franchises. It captures the financial contribution of niche therapies, legacy products, or emerging assets within the company's diversified portfolio. Monitoring this segment helps investors assess the company's ability to monetize a broad pipeline beyond its core market-leading treatments.
Ask your AI about Regeneron Pharmaceuticals's other products — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude